ClinicalTrials.gg
CompletedNCT00386009Updated Jul 9, 2009Results posted

Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

A Phase 2 interventional study of Tadalafil and Placebo in Benign Prostatic Hyperplasia, sponsored by Eli Lilly and Company. Completed at 13 sites in 3 countries. Open to male participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2009-07-09.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
40 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing tadalafil in Prostatic Hyperplasia — 2 open to participants now, 2 under way, none of them phase 3. Tadalafil · Prostatic Hyperplasia.

Enrollment
15th of 26
200 · median 258
Started
2006
with 1 other
Phase 2
4 of 26
none open now
Registered
2nd of 26
by date
Lead sponsor
16 of 26
Eli Lilly and Company

Among the 26 studies testing tadalafil in Prostatic Hyperplasia, this one is the 15th largest by enrollment, is one of 2 that started in 2006, is one of 4 in phase 2, and was the 2nd registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

2 of the 26 studies testing tadalafil in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 40 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing tadalafil in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the function of the bladder and urethra during urinary storage or voiding in men with signs and symptoms of benign prostatic hyperplasia treated with either placebo or tadalafil.

03

Conditions studied

  • Benign Prostatic Hyperplasia

Browse trials for

Keywords

  • Benign Prostatic Hyperplasia
  • Benign Prostatic Hypertrophy
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men 40 years of age or older with Lower Urinary Tract Symptoms (LUTS) with a total International Prostate Symptom Score (IPSS) greater than or equal to 13 at Visit 1.
  • Agree not to use any other approved or experimental medications for Benign Prostate Hyperplasia (BPH)-Lower Urinary Tract Symptoms, including alpha blockers, 5-alpha reductase inhibitors, PDE5 inhibitors, or herbal preparations at any time during the study.
  • Have not taken finasteride or dutasteride therapy for at least 4 months prior to Visit 2; have not taken any other LUTS therapy (including herbal preparations) or PDE5 inhibitors for at least 4 weeks prior to Visit 2.
  • Have had BPH-LUTS for greater than 6 months prior to Visit 1.

Exclusion criteria

Exclusion Criteria:

  • Any pelvic surgical procedure on the urinary tract, including minimally invasive BPH-LUTS therapies and penile implant surgery.
  • History of urethral obstruction due to stricture, valves, sclerosis, or tumor.
  • Current neurologic disease or condition associated with neurogenic bladder (for example, Parkinson's disease, multiple sclerosis).
  • History of cardiac conditions including myocardial infarction, bypass surgery, angioplasty or stent placement for a specified time before starting the study.
  • History of angina requiring treatment with nitrates.
  • Prostate Specific Antigen (PSA) greater than 10 nanogram/milliliter (ng/ml) at Visit 1.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
200 participants (actual)

Study arms

  • Placebo comparator
    1

    Placebo

    Drug: Placebo

  • Active comparator
    2

    tadalafil

    Drug: Tadalafil

Interventions

  • 20 mg tadalafil tablet taken by mouth once a day for 12 weeks.

    Also known as: LY450190, Cialis, IC351

  • DrugPlacebo

    Placebo tablet taken by mouth once a day for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to 12 Week Endpoint in Detrusor Pressure at Peak Urinary Flow Rate (PdetQmax)

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Change From Baseline to 12 Week Endpoint in Peak Urinary Flow Rate (Qmax) Measured During Free-Flow Studies

    Qmax was measured during free-flow tests using a standard calibrated flow meter.

    Time frame: Baseline and 12 weeks

  2. Change From Baseline to 12 Week Endpoint in Mean Urinary Flow Rate (Qave) Measured During Free-Flow Studies

    Qave was measured during free-flow tests using a standard calibrated flow meter.

    Time frame: Baseline and 12 weeks

  3. Change From Baseline to 12 Week Endpoint in Volume of Voided Urine (Vcomp) Measured During Free-Flow Studies

    Time frame: Baseline and 12 weeks

  4. Change From Baseline to 12 Week Endpoint in Postvoid Residual Volume (PVRcath) Measured During Free-Flow Studies

    PVRcath is the volume of urine remaining int he bladder after voiding, measured by catheterization.

    Time frame: Baseline and 12 weeks

  5. Change From Baseline to 12 Week Endpoint in Total Bladder Capacity Measured During Free-Flow Studies

    Total bladder capacity was defined as Vcomp + PVRcath (obtained when the bladder was full).

    Time frame: Baseline and 12 weeks

  6. Change From Baseline to 12 Week Endpoint in Bladder Voiding Efficiency (BVE) Measured During Free-Flow Studies

    Bladder voiding efficiency was defined as (Vcomp/total bladder capacity) X 100 (obtained when the bladder was full).

    Time frame: Baseline and 12 weeks

  7. Change From Baseline to 12 Week Endpoint in Peak Urinary Flow Rate (Qmax) Measured During Pressure-Flow Studies

    Qmax was measured duirng pressure-flow tests.

    Time frame: Baseline and 12 weeks

  8. Change From Baseline to 12 Week Endpoint in Mean Urinary Flow Rate (Qave) Measured During Pressure-Flow Studies

    Qave was measured during pressure-flow tests.

    Time frame: Baseline and 12 weeks

  9. Change From Baseline to 12 Week Endpoint in Volume of Voided Urine (Vcomp) Measured During Pressure-Flow Studies

    Vcomp was defined as the volume of voided urine measured during pressure-flow tests.

    Time frame: Baseline and 12 weeks

  10. Change From Baseline to 12 Week Endpoint in Maximum Detrusor Pressure (Max Pdet) Measured During Pressure-Flow Studies

    Max Pdet was defined as the maximum detrusor pressure observed during voiding.

    Time frame: Baseline and 12 weeks

  11. Change From Baseline to 12 Week Endpoint in Bladder Contractility Index (BCI) Measured During Pressure-Flow Studies

    BCI was derived from the equation PdetQmax + 5Qmax. Scores: \<100 means weak, 100-150 menas normal, \>150 means strong. A decrease means a decrease in contractility of the bladder.

    Time frame: Baseline and 12 weeks

  12. Change From Baseline to 12 Week Endpoint in Bladder Outlet Obstruction Index (BOOI) Measured During Pressure-Flow Studies

    BOOI, formerly known as the Abrams-Griffith number, was derived from the equation PdetQmax - 2Qmax. Scores: \<20 means unobstructed, 20-40 means equivocol, \>40 means obstructed. An increase means worsening of obstruction, a decreased means lessening of obstruction (improvement).

    Time frame: Baseline and 12 weeks

  13. Presence of Involuntary Detrusor Contractions During Bladder Filling

    Time frame: Baseline and 12 weeks

  14. Change From Baseline to 12 Week Endpoint in Bladder Volume at First Involuntary Detrusor Contraction

    Assessed in participants with involuntary detrusor contractions during the bladder filling at both baseline and endpoint.

    Time frame: Baseline and 12 weeks

  15. Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Total Score

    The IPSS Total Score is obtained by combining the scores of the responses to the 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.

    Time frame: 12 weeks

  16. Clinically Adverse and Statistically Significant Changes From Baseline to 12 Week Endpoint in Laboratory Tests

    Laboratory tests that were statistically significant and clinically adverse would be reported for safety.

    Time frame: Baseline and 12 weeks

07

Results

Posted Jun 23, 2009

Participant flow

Participant flow — Overall Study
MilestonePlaceboTadalafil
Started10199
Completed9289
Not completed910
Withdrew: Adverse event02
Withdrew: Death10
Withdrew: Entry criteria not met02
Withdrew: Lost to follow-up11
Withdrew: Protocol violation10
Withdrew: Sponsor decision11
Withdrew: Withdrawal by subject54

Outcome measures

PrimaryChange From Baseline to 12 Week Endpoint in Detrusor Pressure at Peak Urinary Flow Rate (PdetQmax)
Time frame:
Baseline and 12 weeks
Reported as:
Mean · centimeters of water (cm H20)
Change From Baseline to 12 Week Endpoint in Detrusor Pressure at Peak Urinary Flow Rate (PdetQmax)
centimeters of water (cm H20)PlaceboTadalafil
Baseline54.83 ± 27.3656.87 ± 29.67
Change from Baseline to 12 Week Endpoint1.92 ± 19.71-2.95 ± 15.92
Statistical analysis
  • Placebo vs Tadalafil · ANOVA · p = 0.068 (P-value for Change from Baseline to 12 Week Endpoint. Change = Endpoint minus baseline.)
SecondaryChange From Baseline to 12 Week Endpoint in Peak Urinary Flow Rate (Qmax) Measured During Free-Flow Studies

Qmax was measured during free-flow tests using a standard calibrated flow meter.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · milliliters per second
Change From Baseline to 12 Week Endpoint in Peak Urinary Flow Rate (Qmax) Measured During Free-Flow Studies
milliliters per secondPlaceboTadalafil
Baseline13.03 ± 7.3414.75 ± 10.70
Change from Baseline to 12 Week Endpoint0.52 ± 7.830.01 ± 8.83
Statistical analysis
  • Placebo vs Tadalafil · ANOVA · p = 0.626 (P-value for Change from Baseline to 12 Week Endpoint. Change = Endpoint minus baseline.)
SecondaryChange From Baseline to 12 Week Endpoint in Mean Urinary Flow Rate (Qave) Measured During Free-Flow Studies

Qave was measured during free-flow tests using a standard calibrated flow meter.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · millilters per second
Change From Baseline to 12 Week Endpoint in Mean Urinary Flow Rate (Qave) Measured During Free-Flow Studies
millilters per secondPlaceboTadalafil
Baseline7.10 ± 4.377.23 ± 4.18
Change from Baseline to 12 Week Endpoint-0.01 ± 4.111.00 ± 3.04
Statistical analysis
  • Placebo vs Tadalafil · ANOVA · p = 0.113 (P-value for Change from Baseline to 12 Week Endpoint. Change = Endpoint minus baseline.)
SecondaryChange From Baseline to 12 Week Endpoint in Volume of Voided Urine (Vcomp) Measured During Free-Flow Studies
Time frame:
Baseline and 12 weeks
Reported as:
Mean · milliliters
Change From Baseline to 12 Week Endpoint in Volume of Voided Urine (Vcomp) Measured During Free-Flow Studies
millilitersPlaceboTadalafil
Baseline258.56 ± 134.21268.22 ± 149.77
Change from Baseline to 12 Week Endpoint-4.10 ± 151.82-5.17 ± 151.73
Statistical analysis
  • Placebo vs Tadalafil · ANOVA · p = 0.837 (P-value for Change from Baseline to 12 Week Endpoint. Change = Endpoint minus baseline.)
SecondaryChange From Baseline to 12 Week Endpoint in Postvoid Residual Volume (PVRcath) Measured During Free-Flow Studies

PVRcath is the volume of urine remaining int he bladder after voiding, measured by catheterization.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · milliliters
Change From Baseline to 12 Week Endpoint in Postvoid Residual Volume (PVRcath) Measured During Free-Flow Studies
millilitersPlaceboTadalafil
Baseline59.62 ± 66.7448.99 ± 65.73
Change from Baseline to 12 Week Endpoint-1.85 ± 80.92-9.13 ± 70.36
Statistical analysis
  • Placebo vs Tadalafil · ANOVA · p = 0.400 (P-value for Change from Baseline to 12 Week Endpoint. Change = Endpoint minus baseline.)
SecondaryChange From Baseline to 12 Week Endpoint in Total Bladder Capacity Measured During Free-Flow Studies

Total bladder capacity was defined as Vcomp + PVRcath (obtained when the bladder was full).

Time frame:
Baseline and 12 weeks
Reported as:
Mean · milliliters
Change From Baseline to 12 Week Endpoint in Total Bladder Capacity Measured During Free-Flow Studies
millilitersPlaceboTadalafil
Baseline327.95 ± 165.66316.79 ± 187.31
Change from Baseline to 12 Week Endpoint-17.53 ± 182.62-14.88 ± 187.10
Statistical analysis
  • Placebo vs Tadalafil · ANOVA · p = 0.864 (P-value for Change from Baseline to 12 Week Endpoint. Change = Endpoint minus baseline.)
SecondaryChange From Baseline to 12 Week Endpoint in Bladder Voiding Efficiency (BVE) Measured During Free-Flow Studies

Bladder voiding efficiency was defined as (Vcomp/total bladder capacity) X 100 (obtained when the bladder was full).

Time frame:
Baseline and 12 weeks
Reported as:
Mean · milliliters
Change From Baseline to 12 Week Endpoint in Bladder Voiding Efficiency (BVE) Measured During Free-Flow Studies
millilitersPlaceboTadalafil
Baseline84.01 ± 14.5685.85 ± 13.44
Change from Baseline to 12 Week Endpoint-0.52 ± 16.311.85 ± 16.22
Statistical analysis
  • Placebo vs Tadalafil · ANOVA · p = 0.340 (P-value for Change from Baseline to 12 Week Endpoint. Change = Endpoint minus baseline.)
SecondaryChange From Baseline to 12 Week Endpoint in Peak Urinary Flow Rate (Qmax) Measured During Pressure-Flow Studies

Qmax was measured duirng pressure-flow tests.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · milliliters per second
Change From Baseline to 12 Week Endpoint in Peak Urinary Flow Rate (Qmax) Measured During Pressure-Flow Studies
milliliters per secondPlaceboTadalafil
Baseline9.49 ± 4.9010.29 ± 4.46
Change from Baseline to 12 Week Endpoint0.50 ± 2.910.38 ± 2.92
Statistical analysis
  • Placebo vs Tadalafil · ANOVA · p = 0.838 (P-value for Change from Baseline to 12 Week Endpoint. Change = Endpoint minus baseline.)
SecondaryChange From Baseline to 12 Week Endpoint in Mean Urinary Flow Rate (Qave) Measured During Pressure-Flow Studies

Qave was measured during pressure-flow tests.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · milliliters per second
Change From Baseline to 12 Week Endpoint in Mean Urinary Flow Rate (Qave) Measured During Pressure-Flow Studies
milliliters per secondPlaceboTadalafil
Baseline4.67 ± 2.445.50 ± 2.68
Change from Baseline to 12 Week Endpoint0.45 ± 1.660.58 ± 1.91
Statistical analysis
  • Placebo vs Tadalafil · ANOVA · p = 0.609 (P-value for Change from Baseline to 12 Week Endpoint. Change = Endpoint minus baseline.)
SecondaryChange From Baseline to 12 Week Endpoint in Volume of Voided Urine (Vcomp) Measured During Pressure-Flow Studies

Vcomp was defined as the volume of voided urine measured during pressure-flow tests.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · milliliters
Change From Baseline to 12 Week Endpoint in Volume of Voided Urine (Vcomp) Measured During Pressure-Flow Studies
millilitersPlaceboTadalafil
Baseline294.10 ± 147.74296.64 ± 143.30
Change from Baseline to 12 Week Endpoint3.31 ± 140.4613.51 ± 99.64
Statistical analysis
  • Placebo vs Tadalafil · ANOVA · p = 0.427 (P-value for Change from Baseline to 12 Week Endpoint. Change = Endpoint minus baseline.)
SecondaryChange From Baseline to 12 Week Endpoint in Maximum Detrusor Pressure (Max Pdet) Measured During Pressure-Flow Studies

Max Pdet was defined as the maximum detrusor pressure observed during voiding.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · centimeters of water (cm H20)
Change From Baseline to 12 Week Endpoint in Maximum Detrusor Pressure (Max Pdet) Measured During Pressure-Flow Studies
centimeters of water (cm H20)PlaceboTadalafil
Baseline67.13 ± 31.6672.20 ± 38.65
Change from Baseline to 12 Week Endpoint-0.48 ± 28.19-2.11 ± 24.08
Statistical analysis
  • Placebo vs Tadalafil · ANOVA · p = 0.838 (P-value for Change from Baseline to 12 Week Endpoint. Change = Endpoint minus baseline.)
SecondaryChange From Baseline to 12 Week Endpoint in Bladder Contractility Index (BCI) Measured During Pressure-Flow Studies

BCI was derived from the equation PdetQmax + 5Qmax. Scores: \<100 means weak, 100-150 menas normal, \>150 means strong. A decrease means a decrease in contractility of the bladder.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · units on a nomogram
Change From Baseline to 12 Week Endpoint in Bladder Contractility Index (BCI) Measured During Pressure-Flow Studies
units on a nomogramPlaceboTadalafil
Baseline102.28 ± 32.84108.32 ± 32.14
Change from Baseline to 12 Week Endpoint4.43 ± 20.86-1.04 ± 20.37
Statistical analysis
  • Placebo vs Tadalafil · ANOVA · p = 0.090 (P-value for Change from Baseline to 12 Week Endpoint. Change = Endpoint minus baseline.)
SecondaryChange From Baseline to 12 Week Endpoint in Bladder Outlet Obstruction Index (BOOI) Measured During Pressure-Flow Studies

BOOI, formerly known as the Abrams-Griffith number, was derived from the equation PdetQmax - 2Qmax. Scores: \<20 means unobstructed, 20-40 means equivocol, \>40 means obstructed. An increase means worsening of obstruction, a decreased means lessening of obstruction (improvement).

Time frame:
Baseline and 12 weeks
Reported as:
Mean · units on a nomogram
Change From Baseline to 12 Week Endpoint in Bladder Outlet Obstruction Index (BOOI) Measured During Pressure-Flow Studies
units on a nomogramPlaceboTadalafil
Baseline35.84 ± 30.8736.28 ± 33.14
Change from Baseline to 12 Week Endpoint0.92 ± 22.10-3.71 ± 17.56
Statistical analysis
  • Placebo vs Tadalafil · ANOVA · p = 0.113 (P-value for Change from Baseline to 12 Week Endpoint. Change = Endpoint minus baseline.)
SecondaryPresence of Involuntary Detrusor Contractions During Bladder Filling
Time frame:
Baseline and 12 weeks
Reported as:
Number · participants
Presence of Involuntary Detrusor Contractions During Bladder Filling
participantsPlaceboTadalafil
Present at Baseline3328
Not Present at Baseline5856
Present at Endpoint3631
Not Present at Endpoint5553
Present at Both Baseline and Endpoint2218
Present at Baseline Only1110
Present at Endpoint Only1413
Present at Neither Baseline nor Endpoint4443
SecondaryChange From Baseline to 12 Week Endpoint in Bladder Volume at First Involuntary Detrusor Contraction

Assessed in participants with involuntary detrusor contractions during the bladder filling at both baseline and endpoint.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · milliliters
Change From Baseline to 12 Week Endpoint in Bladder Volume at First Involuntary Detrusor Contraction
millilitersPlaceboTadalafil
Baseline120.55 ± 82.50164.00 ± 108.31
Change from Baseline to 12 Week Endpoint27.86 ± 128.2028.56 ± 106.67
SecondaryChange From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Total Score

The IPSS Total Score is obtained by combining the scores of the responses to the 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.

Time frame:
12 weeks
Reported as:
Mean · units on a scale
Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Total Score
units on a scalePlaceboTadalafil
Baseline22.01 ± 5.7221.46 ± 5.63
Change from Baseline to 12 Week Endpoint-5.04 ± 6.93-9.13 ± 6.90
Statistical analysis
  • Placebo vs Tadalafil · ANOVA · p = <0.001 (P-value for Change from Baseline to 12 Week Endpoint. Change = Endpoint minus baseline.)
SecondaryClinically Adverse and Statistically Significant Changes From Baseline to 12 Week Endpoint in Laboratory Tests

Laboratory tests that were statistically significant and clinically adverse would be reported for safety.

Time frame:
Baseline and 12 weeks
Reported as:
Number · significant and clinically adverse labs
Clinically Adverse and Statistically Significant Changes From Baseline to 12 Week Endpoint in Laboratory Tests
significant and clinically adverse labsPlaceboTadalafil
Clinically Adverse and Statistically Significant Changes From Baseline to 12 Week Endpoint in Laboratory Tests0 ± 0.410 ± 0.33

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo———
Tadalafil———
Most frequent serious events
Most frequent serious events
EventPlaceboTadalafil
CellulitisInfections and infestations0/1011/99
PneumoniaInfections and infestations0/1011/99
Humerus fractureInjury, poisoning and procedural complications0/1011/99
Skin lacerationInjury, poisoning and procedural complications0/1011/99
PleurisyRespiratory, thoracic and mediastinal disorders0/1011/99
Myocardial infarction/DeathCardiac disorders1/1010/99
HypoaesthesiaNervous system disorders1/1010/99
Most frequent other events
Showing 10 of 78
Most frequent other events
EventPlaceboTadalafil
DyspepsiaGastrointestinal disorders0/1018/99
HeadacheNervous system disorders3/1017/99
Back painMusculoskeletal and connective tissue disorders3/1015/99
Gastrooesophageal reflux diseaseGastrointestinal disorders0/1013/99
DizzinessNervous system disorders3/1010/99
GastritisGastrointestinal disorders0/1012/99
InfluenzaInfections and infestations1/1012/99
Upper respiratory tract infectionInfections and infestations2/1012/99
Hepatic enzyme increasedInvestigations0/1012/99
ArthralgiaMusculoskeletal and connective tissue disorders0/1012/99

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboTadalafilTotal
Mean59.03 ± 9.6958.16 ± 8.8258.60 ± 9.26
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTadalafilTotal
Female000
Male10199200
Region of Enrollment
Region of Enrollment(participants)PlaceboTadalafilTotal
United States9995194
Canada246
Baseline Benign Prostatic Hyperplasia (BPH) Lower Urinary Tract Symptom (LUTS) Severity
Baseline Benign Prostatic Hyperplasia (BPH) Lower Urinary Tract Symptom (LUTS) Severity(participants)PlaceboTadalafilTotal
Moderate (IPSS <20)343569
Severe (IPSS ≥20)6662128
Missing Baseline Measure123
Bladder Outlet Obstruction Index (BOOI)
Bladder Outlet Obstruction Index (BOOI)(participants)PlaceboTadalafilTotal
Obstructed (BOOI > 40)333467
Equivocal (BOOI 20-40)353469
Unobstructed (BOOI < 20)333164
Duration of Benign Prostatic Hyperplasia Lower Urinary Tract Symptoms (BPH LUTS)
Duration of Benign Prostatic Hyperplasia Lower Urinary Tract Symptoms (BPH LUTS)(participants)PlaceboTadalafilTotal
6 months to 1 year131225
1 year to 3 years363066
> 3 years5257109
Erectile Dysfunction Severity
Erectile Dysfunction Severity(participants)PlaceboTadalafilTotal
Mild202242
Moderate313162
Severe9514
Presence of Erectile Dysfunction
Presence of Erectile Dysfunction(participants)PlaceboTadalafilTotal
Yes6058118
No414182

8 further baseline measures are reported on the registry.

08

Study locations

13 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Newport Beach, California 92660, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tarzana, California 91356, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Middlebury, Connecticut 06762, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Orlando, Florida 32803, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chicago, Illinois 60611, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fort Wayne, Indiana 46825, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Garden City, New York 11530, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Antonio, Texas 78229, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Patras, 26500, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Thessaloniki, 56429, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Coimbra, 3000-076, Portugal
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lisbon, 1549-008, Portugal
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Porto, 4200-319, Portugal
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2006
First posted
Oct 11, 2006
Start
Oct 2006
Primary completionActual
May 2008
CompletionActual
May 2008
Results first posted
Jun 23, 2009
Last update
Jul 9, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00386009
Collaborators
ICOS Corporation
First posted
Oct 11, 2006
Start date
Oct 2006
Primary completion
May 2008
Completion
May 2008
Results posted
Jun 23, 2009
Last update
Jul 9, 2009

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion